Sh­iono­gi miss­es pri­ma­ry end­point in Phase 3 for Covid-19 an­tivi­ral

Sh­iono­gi’s once-dai­ly Covid-19 an­tivi­ral en­sitrelvir missed the pri­ma­ry end­point in a Phase 3 study, two months af­ter scor­ing full ap­proval in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.